Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466571 | 1.00 | TSHR (0.51) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL1065078 | 1.00 | TSHR (0.51) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL240719 | 1.00 | TSHR (0.51) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL2665681 | 0.90 | L3MBTL1 (0.54) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL9625796 | 0.90 | L3MBTL1 (0.54) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL15726196 | 0.89 | TSHR (0.46) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL15726193 | 0.89 | TSHR (0.46) | TSHRKMT2AL3MBTL1LMNAGAA | |
| SCHEMBL11542774 | 0.84 | ERCC1 (0.51) | KMT2AALDH1A1CYP1A2MEN1KDM4E | |
| SCHEMBL11537599 | 0.84 | ERCC1 (0.51) | KMT2AALDH1A1CYP1A2MEN1KDM4E | |
| SCHEMBL11537593 | 0.84 | ERCC1 (0.51) | KMT2AALDH1A1CYP1A2MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2024245310-A1 | THIAZOLYL OR THIADIAZOLYL AMIDES DERIVATIVES AND USE THEREOF | NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-12-05 | — | — | WO | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-111741955-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-30 | — | — | US | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006045119-A9 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1656379-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006045119-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | THOMPSON WAYNE (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019222-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | TSHR 3581/4885KMT2A 2123/4885L3MBTL1 2018/4885 |
| US-11813267-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | TSHR 4282/4885KMT2A 1053/4885L3MBTL1 2098/4885 |
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | TSHR 4246/4885KMT2A 1065/4885L3MBTL1 2056/4885 |
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | TSHR 3705/4885KMT2A 2899/4885L3MBTL1 3495/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | TSHR 2487/4885KMT2A 2296/4885L3MBTL1 1142/4885 |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | TOP1, TOP2A, TOP2B | TSHR 4108/4885KMT2A 1090/4885L3MBTL1 2984/4885 |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | GRIN2B, GRIN1, GRIN2A | TSHR 2076/4885KMT2A 1370/4885L3MBTL1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.